Fig. 7: Targeting LAG3 and PD-L1 in tumors with NF1, TSC1, or TβRII deficiency. | Nature Communications

Fig. 7: Targeting LAG3 and PD-L1 in tumors with NF1, TSC1, or TβRII deficiency.

From: Loss of tumor suppressors promotes inflammatory tumor microenvironment and enhances LAG3+T cell mediated immune suppression

Fig. 7: Targeting LAG3 and PD-L1 in tumors with NF1, TSC1, or TβRII deficiency.The alternative text for this image may have been generated using AI.

A Heatmap for the expression of NF1, TSC1, and TβRII in breast cancer subtypes (TCGA dataset). B Kaplan–Myer survival curve of breast cancer patients with the expression levels of NF1, TSC1, or TβRII in basal subtype breast cancer. C TS-Imm signature gene list, and the predicted Kaplan–Myer survival curve of all and basal, Her2+, Lum A/B subtype breast cancer patients. D Heatmap for the correlation of TS expression with LAG3 (left) and in subtypes of breast cancer (right), TCGA dataset. E upper: Schematic of combination treatment of anti-LAG3, anti-PD-L1, and Pac in 4T1 preclinical mouse model. lower: metastatic nodule counts normalized to tumor weight. F CyTEK analysis of primary tumors with NF1, TSC1, or TβRII deficiency from mice that were treated with anti-LAG3, anti-PD-L1, and Pac. Upper: percentage of CD4 and Treg cells; Lower: percentage of CD8, LAG3+ CD8, and PD-1+ CD8 T cells (n = 4). G Number of metastatic nodules per tumor weight in mice treated with anti-LAG3, IDO1 inhibitor, and Pac (left); LAG3+ CD8 and LAG3+ CD4 T cells from anti-LAG3 antibody, IDO1 inhibitor and Pac treatment (n = 4) (middle and right panels). Statistical significance was determined by logrank test for (B) and (C); one-way ANOVA followed by Sidak’s test for E; two-tailed Student t-test for (F) and (G). All graphs show mean ± s.d.

Back to article page